In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare coverage criteria

This article was originally published in The Gray Sheet

Executive Summary

Town hall meeting originally planned for Aug. 31 to discuss the agency's May 16 "notice of intent" on coverage criteria is rescheduled for Sept. 13. HCFA plans to issue a Federal Register notice the week of Aug. 28 rescinding the earlier date. Issues to be addressed at the town hall meeting include increased evidence burden in coverage reviews and withdrawal of coverage for older technologies. The agency also is expected to announce that it will handle cost issues through its payment division, rather than as part of coverage decisions (1"The Gray Sheet" Aug. 21, 2000, p. 6)

You may also be interested in...



HCFA Expected To Offer Compromise On Cost In Proposed Coverage Criteria

HCFA plans to eliminate or significantly scale back the role of cost from its proposed criteria for making Medicare coverage decisions, according to agency staff.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 
UsernamePublicRestriction

Register

MT013787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel